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Background/Aim. In randomised controlled trials (RCTs) of ursodeoxycholic acid (UDCA), although serum bilirubin is frequently
reduced, its effect on disease progression and mortality is unclear. As serum albumin is an established independent prognostic
marker, one might expect less deterioration of serum albumin values in a UDCA-treated group. We therefore modelled the typical
evolution of serum bilirubin and albumin levels over time in UDCA-untreated patients and compared it with the observed levels in
UDCA RCTs.Methods. Multilevel modelling was used to relate the evolution of serum albumin to serum bilirubin and time since
patient referral. For each consideredRCT, the derivedmodelwas used to predict the relationship between finalmean serumalbumin
and bilirubin concentration, adjusted for mean serum albumin at referral and followup duration. Results. Five RCTs were eligible
in terms of available data, of which two had long followup. In all trials, serum albumin did not significantly differ between UDCA-
and placebo-treated patients, despite the UDCA effect on serum bilirubin.Therefore, there is no evidence over time for changes or
maintenance of albumin levels for UDCA-treated patients above the levels predicted for placebo-treated patients. Conclusions. Our
findings suggest that UDCA does not alter serum albumin in a way that is consistent with its effect on serum bilirubin. Therefore,
reductions in serum bilirubin of UDCA-treated PBC do not parallel another validated and independent prognostic marker, further
questioning the validity of serum bilirubin reduction with UDCA as a surrogate therapeutic marker.
1. Introduction
Primary biliary cirrhosis (PBC) is a slowly progressive disease
characterised by the destruction of smaller size bile ducts
leading to hepatic fibrosis, cirrhosis, and eventually liver fail-
ure [1]. Currently, the only approved treatment is ursodeoxy-
cholic acid (UDCA), which is claimed to modify disease
progression [2]. However, separate meta-analyses have not
shown benefit of UDCA in terms of survival, transplantation
rates, or complications of disease [3–5].
Serum bilirubin and albumin levels are well-established
and important prognostic markers for time to death or trans-
plantation in untreated patients, being universally present in
all disease prognosticmodels [6–8]. However, in the presence
of treatment, an objective assessment of their quality and
reliability as surrogate endpoints for survival has not been
carried out despite adequate published methodology [9–11].
Although a serum bilirubin rise is clearly linked to shortened
survival, the effect of a UDCA-mediated decrease is unclear
[3–5], as patient survival and disease progression are not
demonstrably improved. Therefore, it can be considered
premature and possibly unreliable to draw conclusions on the
efficacy of treatment based solely on serum bilirubin. This
would be particularly pertinent when considering UDCA, as
other surrogate endpoints have not been shown to be different
between UDCA and placebo or no treatment in randomised
trials.
In order to further assess the benefit ofUDCAas a specific
therapy in PBC, we considered the relationship between
serum bilirubin and albumin over time in a cohort of un-
treated patients, with the expected rise in bilirubin being
associated with a fall in serum albumin. We then evaluated
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this relationship in the UDCA trials with the expectation
of observing a slower fall in serum albumin in the UDCA
groups, if indeed treatment was delaying disease progression.
Absence of this effect would raise further doubt on the true
impact of UDCA as a disease modifier in PBC, particularly if
this were to be true in trials with very long followup and sub-
stantial reductions in serum bilirubin concentrations in the
UDCA-treated groups.
2. Patients and Methods
We used a cohort of PBC patients untreated with UDCA and
independent of randomised trials in order to describe the
evolution of serum bilirubin and albumin levels over time.
This reference cohort consisted of 289 patients referred to the
Royal Free Hospital, London, between January 1, 1977, and
December 31, 1989. Full details are given elsewhere [17, 18]. All
patients were untreated with UDCA and presented without
variceal bleeding, a criterion of exclusion in the randomised
trials of UDCA. Patients were followed up from referral for a
median of 3.3 years (10th and 90th percentiles of 0.2 and 9.1
years). During followup, serum bilirubin and albumin levels
were routinely monitored, usually every 3–6 months. The
average number of measurements per patient was 18 (10th
and 90th percentiles of 6 and 33).Themeans (standard error)
of bilirubin and albumin concentrations at referral were
33.7 umol/L (4.87) and 39.9 g/L (0.42), respectively.
Using the reference cohort, we modelled the repeated
measurements of serum albumin and log
10
(bilirubin),
together with time from referral, to establish the typical
relationship between them.We investigatedwhether this rela-
tionship depended on age and sex. A random effects model
was used [8], which is a classicalmodel for repeatedmeasures.
For each subject, all successivemeasurements of bilirubin and
albumin together with the time of measurement are consid-
ered. A hierarchicalmodelling approachwas adopted to allow
subject specific profiles to be modelled. It is clear that
this guarantees not only individual predictions but also the
prediction of the means. Model building was carried out
using backward selection, with testing at the 5% level of sig-
nificance, to arrive at the simplest satisfactory model for the
mean and variance structure. Despite considering the sim-
plest structure for the residuals variance, ourmodel with both
random intercept and random slope on time ensures that
correlation between repeated measurements is appropriately
accounted for. The statistical software MLwiN version 2.1d
was used [19].
It might be considered that dropouts might affect our
results and interpretation of the relationship between serum
bilirubin and albumin concentrations, particularly if a drop-
out could not be predicted using earlier response values
or variables. Our modelling adopted a likelihood approach,
which enables an unbiased estimate even when the patients
dropping outmay be those with a particular bilirubin or albu-
min profile. Indeed, themodelling approach does not assume
that dropouts are occurring completely at random (i.e., drop-
outs not related to disease progression) but allows for this,
eliminating potential bias.
Table 1: Model parameter estimates.
Parameters Estimate(standard error) Description
𝛽
0 9.57 (1.63) Intercept
𝛽
1 3.73 (1.15)
log10 (bilirubin 𝑡 days after
referral (𝜇mol/L))
𝛽
2 −1.68 (0.35)
{log10 (bilirubin 𝑡 days after
referral (𝜇mol/L))}
𝛽
3 −2.3 × 10−3 (4.85 × 10−4) Time
𝛽
4 0.720 (0.031) Albumin at baseline (g/L)
Having established the typical relationship between albu-
min, log
10
(bilirubin), and time from referral in patients
untreated with UDCA, we compared this relationship with
that seen in clinical trials of UDCA included in the meta-
analysis [5] and from UDCA trial reports [12–16]. This was
done as follows. For each eligible trial, our reference cohort
model was used to predict the albumin levels one would
expect to see at the end of the trial, given the initial albumin,
final bilirubin, and length of followup. For this purpose, “time
since randomisation” in the clinical trial was equated to “time
since referral” in the reference cohort. We calculated 95%
confidence intervals for our albumin concentration predic-
tions and compared themwith the published 95% confidence
intervals for the end of trial albumin concentrations.We only
included UDCA trials in which details of biochemical values
were available at the start and end of the therapy.
3. Results
3.1. Model for Reference Cohort. The final model related
serum albumin 𝑡 days after referral to (i) bilirubin 𝑡 days after
referral, (ii) t the number of days after referral, and (iii) albu-
min at referral. Differences in this relationship by sex and age
were not statistically significant. The model is as follows:
albumin 𝑡 days after randomisation (g/L) = 𝛽
0
+ 𝛽
1
× log
10
(bilirubin 𝑡 days after referral (𝜇mol/L))
+ 𝛽
2
× {log
10
(bilirubin 𝑡 days after referral (𝜇mol/L))}2
+ 𝛽
3
× 𝑡 + 𝛽
4
𝑥 (albumin at baseline (g/L)) ,
(1)
with fixed parameter estimates shown in Table 1, random
parameter estimates shown in the Appendix.
3.2. Evaluation ofUDCATrials. Six of the 11 identifiedUDCA
trials in the meta-analysis [5] could not be evaluated as they
gave no information on serum albumin levels at randomi-
sation nor at the end of followup [20–25]. Furthermore,
although someof the 5 eligible trials had additional longer fol-
lowup [12–16], with use of UDCA (placebo patients changed
to UDCA), unfortunately, there was no information on either
serumalbumin or serumbilirubin levels at the end of the con-
version phase on UDCA therapy, so this additional followup
could not be used.
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Table 2: Mean ± standard error of serum albumin (g/L) and bilirubin (𝜇mol/L) levels at baseline and end of the followup (before crossover,
if any) for considered trials.
First bilirubin
UDCA/no UDCA
Last bilirubin
UDCA/no UDCA
First albumin
UDCA/no UDCA
Last albumin
UDCA/no UDCA Median followup
Poupon et al. [12], 1991 23.2 ± 2.6 𝜇mol/L21.2 ± 2.5 𝜇mol/L
12.3 ± 0.9𝜇mol/L
17.9 ± 2.2 𝜇mol/L
38.9 ± 0.5 g/L
40.1 ± 0.5 g/L
39.8 ± 0.6 g/L
39.8 ± 0.7 g/L 24 months
Battezzati et al. [13], 1993 31.5 ± 4.0 𝜇mol/L32.5 ± 3.7 𝜇mol/L
27.2 ± 3.4 𝜇mol/L
32.8 ± 4.7 𝜇mol/L
40.7 ± 1.0 g/L
40.9 ± 0.8 g/L
41.9 ± 0.9 g/L
40.4 ± 0.8 g/L 9 months
Vuoristo et al. [14], 1995 22.7 ± 3.4 𝜇mol/L25.5 ± 6.8 𝜇mol/L
20.4 ± 6.8 𝜇mol/L
15.3 ± 1.7𝜇mol/L
35.0 ± 0.7 g/L
35.6 ± 0.7 g/L
35.7 ± 0.1 g/L
35.3 ± 0.6 g/L 25 months
Pares et al. [15], 2000 22.1 ± 1.7𝜇mol/L27.2 ± 3.4 𝜇mol/L
23.8 ± 3.4 𝜇mol/L
35.7 ± 3.1 𝜇mol/L
41.9 ± 0.6 g/L
40.6 ± 0.6 g/L
40.3 ± 0.5 g/L
40.3 ± 0.6 g/L 3.4 years
Papatheodoridis et al. [16], 2002∗ 23.8 ± 0.78𝜇mol/L22.1 ± 1.02𝜇mol/L
35.7 ± 5.7 𝜇mol/L
39.1 ± 8.5𝜇mol/L
37 ± 5 g/L
38 ± 4 g/L
32 ± 6 g/L
34 ± 5 g/L 7 years
Bilirubin values in mg/dL were converted for the statistical evaluation (1mg/dL = 17.1𝜇mol/L).
∗In this trial, the untreated control group did not receive placebo.
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Figure 1: Reported and predicted levels of serum bilirubin and serum albumin for trials with long follow-up period. Vertical lines represent
95% confidence intervals. First (a) shows the profile of the relationship between serum bilirubin and albumin (solid line) with the 95%
confidence interval (dash line) predicted by the model applied to the trial reported by Papatheodoridis et al. [16]. This trial had a baseline
albumin of 36 g/L and 37 g/L for UDCA and untreated arms, respectively, and amean followup of 7 years. As the number of patients who were
initially assigned to remain untreated were crossed over to UDCA therapy at some point during the study period, the end of followup was
considered the time of crossover for those patients. Superimposed on this in the figure is a point corresponding to the end of trial albumin
and bilirubin level for each of the trial arms (UDCA and placebo), together with the reported 95% confidence interval for albumin. Likewise,
(b) shows the corresponding results for the trial reported by Pares et al. [15], which had a baseline serum albumin of 41.9 g/L and 40.6 g/L for
UDCA and placebo arms, respectively.
As previously described, we identified 5 eligible trials
(Table 2). Two trials had long followup (Papatheodoridis et al.
[16], median followup 7 years, and Pares et al. [15], median
followup 3.4 years).Three trials had short followup (Vuoristo
et al. [14], median followup 2 years; Poupon et al. [12], median
followup 2 years; and Battezzati et al. [13], median followup 9
months). Firstly we focused on the two trials with the longer
followup.
In the trial by Papatheodoridis et al. [16] (Figure 1(a)),
the model from the independent reference cohort for UDCA
untreated patients closely predicts the end of trial albumin
concentration in those treated with UDCA. In other words,
UDCA did not improve the albumin level of patients over
and above that seen in the untreated reference cohort with a
similar followup, baseline albumin, and final bilirubin. Con-
versely, the placebo arm shows a significant improvement in
albumin against the independent reference cohort. This dif-
ference in serum albumin concentrations at the end of the
followup between UDCA, and placebo-treated groups with
respect to the independent reference cohort is consistent with
UDCA having no effect on albumin, a known prognostic
marker in PBC.
In theUDCAarm in the Pares et al. trial [15] (Figure 1(b)),
the serum albumin does improve over and above that pre-
dicted by the reference cohort. However, the placebo arm has
amoremarked improvement in albumin, being further above
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Figure 2: Reported and predicted levels of serum bilirubin and serum albumin for trials with short follow up period. Vertical lines represent
95% confidence intervals. In the Battezzati et al. [13] (b) and Vuoristo et al. [14] (c) trials, when compared with the placebo-treated arm, the
UDCA-treated patients have a serum albumin concentration further above the expected value suggested by their bilirubin. However, in both
these studies the difference between the predicted and observed results does not approach statistical significance at the 5% level. By contrast,
the study by Poupon et al. [12] (a) shows that the placebo-treated patients have a mean albumin level further above their predicted level than
the UDCA patients.
the predicted curve. Therefore, although UDCA has reduced
serum bilirubin, there is no corresponding improvement in
serum albumin over and above the level seen in the placebo
arm.This is also consistent with no UDCA effect on underly-
ing prognosis, as measured by albumin levels.
The results for the three trials with shorter followup are
shown in Figure 2. In theVuoristo et al. [14] and the Battezzati
et al. [13] trials, when compared with the placebo-treated
arm, the UDCA-treated patients have a serum albumin
concentration further above the expected value suggested by
their bilirubin. However, in both of these studies, the differ-
ence between the predicted and observed results does not
approach statistical significance at the 5% level. By contrast,
the study by Poupon et al. [12] shows that the placebo-treated
patients have a mean albumin level further above their pre-
dicted level compared to UDCA patients. Again, this is con-
sistent with no effect of UDCA on underlying prognosis, as
measured by albumin levels.
4. Discussion
In the present study, we assessed the statistical relationship
between serum bilirubin and albumin concentrations during
the natural course of PBC in untreated patients and further
constructed a time model on their relation, since both are
well-established independent predictors of survival and thus
disease progression in PBC. We then compared the relation-
ship seen in the reference cohort between albumin, bilirubin,
and time since referral with that seen in published UDCA
trials. Specifically, the reported reduction in serum bilirubin
levels in UDCA trials was assessed in relation to an accom-
panying and corresponding slower reduction, stabilisation or
even increase in serum albumin concentration, consistent
with improved prognosis.
As a higher concentration in serum albumin is associated
with improved survival, and if UDCA not only lowers biliru-
bin, but also improves prognosis, one would expect to see a
slower fall in the level of albumin (after adjusting for time
and baseline albumin). Therefore, if the observed albumin at
the end of the trial’s followup was lower than that predicted
by the model, given the final bilirubin level and the length
of followup, this would be consistent with UDCA having no
effect on prognosis. Conversely, if it were higher than that pre-
dicted by the model, this would be consistent with UDCA
improving prognosis.
Our model was thus used to predict the serum albumin
concentrations at the conclusion of the five randomised trials
of UDCA that reported end of study albumin, and it com-
pared these predictions with what was actually observed. In
all assessed trials, serum albumin did not significantly differ
between UDCA- and placebo-treated patients, despite the
significant UDCA effect on serum bilirubin. Only three of
these trials showed a significantly different bilirubin/albumin
relationship to the reference cohort. The trials reported by
Poupon et al. [12] and Pares et al. [15] showed no difference
in final albumin levels between the trial arms of placebo and
UDCA. However, relative to the reference cohort, given the
final bilirubin, the final albumin was further above the pre-
diction in the placebo arms for both trials. This is consistent
with UDCA not modifying disease progression as measured
by albumin concentrations.
This conclusion is reinforced by the trial by Papatheodor-
idis et al. [16] which has the longest followup similar to our
reference cohort. Here, in the UDCA arm, the final albumin
level was closely predicted by our model, whereas in the
untreated arm, the albumin level was significantly above that
predicted by the model. In the two other studies [13, 14],
although the final serum albumin was higher in the UDCA
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arm compared to placebo, the difference between the pre-
dicted and observed results did not reach statistical signifi-
cance.
Therefore, the results of these 5 studies show that UDCA
does not affect the disease progression as measured by serum
albumin, and this further supports the results and interpreta-
tion published meta-analysis [3–5] which fail to demonstrate
a beneficial effect of UDCA.
Our findings clearly suggest that serum bilirubin cannot
be taken as a validated surrogate marker of therapeutic bene-
fit. It is recognised that bilirubin concentrations fall within 3
months in UDCA-treated patients and then rise less rapidly
than in nontreated patients.This response can be attributed to
the choleretic effect of UDCA, that is, stimulation of biliary
secretion of bile acids [26], and appears to be merely bio-
chemical, as it does not result in an improvement in liver
synthetic function or in patients’ survival.
The limitations of our approach could be due to possible
differences between the independent reference cohort and
the study populations. However, although we would expect
a cohort referred to a hospital to be more severely ill than
patients taking part in trials, we did exclude patients with
bleeding as a presentation as did the trials.Themean bilirubin
and albumin concentrations in our cohort at referral were
almost the same as those reported by Battezzati et al. [13].The
bilirubin and albumin relationship was closely predicted by
ourmodel in the trial with the longest followup [16], although
bilirubin valueswere lower.Thus, it is reasonable to expect the
pattern of the relationship to be similar in the various groups
of patients, thus making our interpretation valid. Another
potential problem is the change in the assay techniques for
serum albumin over times, which are not detailed in the
reports. Although this could affect the comparison with
respect to the reference cohort, the comparison within a
single trial of UDCA and placebo/untreated groups with
respect to the reference cohort is still valid and not biased
by changes in measurement methodology. This may be the
reason for higher than predicted albumin values in the pla-
cebo/untreated groups.
We did not evaluate the relationship of serum bilirubin
concentrations with the other known or reported prognostic
factors in PBC; the data on prothrombin time was not avail-
able in the randomised trials of UDCA, and neither in our
database, as prothrombin time values are not routinely mea-
sured during followup of PBC patients. Histological progres-
sion, although considered by some to be affected favourably
by UDCA but not by us [27], cannot easily be assessed, as
usually nomore than one biopsy is available in routine clinical
practice, and by nomeans all patients in the UDCA trials had
paired biopsies. Lastly, as regards oedema and/or ascites, it is
difficult to model this variable, as assessing progression of
this is difficult to measure, as compared with the continuous
variables of serum bilirubin and albumin.
We conclude that there is no evidence that UDCA acts
on serum albumin concentrations in a way that is consistent
with its effect on serum bilirubin levels. Given that these are
both independent prognostic markers in PBC and that lower
serum bilirubin concentrations are associated with higher
serum albumin concentrations, this result supports the evi-
dence and the interpretation for the lack of effect ofUDCAon
PBC disease progression as detailed in independent meta-
analyses [3–5]. Therefore, reduction in serum bilirubin con-
centration in UDCA-treated PBC patients cannot be taken as
a validated surrogate marker of therapeutic benefit.
Appendix
To account for the correlation in the repeated measurements
in the data set of the independent reference cohort, the
coefficients of log
10
(bilirubin), time since referral, and the
intercept were allowed to be normally distributed about their
mean estimated values (shown in Table 1). The estimated
variance matrix of this trivariate normal distribution is
(
16.93 5.01 × 10−4 −13.6
5.01 × 10−4 7.41 9.38 × 10−4
−13.6 9.38 × 10−4 30.13
) , (A.1)
where the diagonal elements are the variances of log
10
(biliru-
bin), time since referral, and the intercept, respectively, and
the off-diagonal elements are the covariances between them.
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